Try the modernized beta website. Learn more about the modernization effort.

Key Record Dates Identifier: NCT02496663
Brief Title: Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

First Submitted : July 9, 2015
First Submitted that Met QC Criteria : July 9, 2015
First Posted : July 14, 2015 (Estimate)

Last Update Submitted that Met QC Criteria : July 1, 2021
Last Update Posted : July 2, 2021